Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. 2011

Bettina Weigelin, and Marina Krause, and Peter Friedl
Microscopical Imaging of the Cell, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands.

Immunological control of cancer lesions requires local uptake of tumor-specific antigen followed by the activation and expansion of tumor specific cytotoxic T-lymphocytes (CTL). An efficient effector phase further depends upon the entry of activated CTL into the tumor microenvironment and scanning of tumor tissue, which leads to direct interaction of the CTL with target cells followed by apoptosis induction and shrinkage of the tumor lesion. Whereas the antigens and pathways that lead to efficient activation of tumor-specific CTL are well established, the local mechanisms that enable efficient - or deficient - CTL function in the tumor tissue are poorly understood. Firstly, effector T lymphocytes need to be mobile to reach the tumor lesion. Next, they must physically interact with and scan tumor cells for antigenic MHC/peptide complexes. Lastly, CTLs must undergo activation and functional conjugation with target cells to induce apoptosis either by the release of perforins or the engagement of Fas/FasL. All these steps of effector function are interdependent and require the amoeboid migration of CTL through tissue to reach, engage with and leave encountered cells.

UI MeSH Term Description Entries
D007157 Immunologic Surveillance The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells. Surveillance, Immunologic,Immunological Surveillance,Immunologic Surveillances,Immunological Surveillances,Surveillance, Immunological,Surveillances, Immunologic,Surveillances, Immunological
D002450 Cell Communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP. Cell Interaction,Cell-to-Cell Interaction,Cell Communications,Cell Interactions,Cell to Cell Interaction,Cell-to-Cell Interactions,Communication, Cell,Communications, Cell,Interaction, Cell,Interaction, Cell-to-Cell,Interactions, Cell,Interactions, Cell-to-Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments

Related Publications

Bettina Weigelin, and Marina Krause, and Peter Friedl
June 2003, Current opinion in immunology,
Bettina Weigelin, and Marina Krause, and Peter Friedl
May 2017, Nature communications,
Bettina Weigelin, and Marina Krause, and Peter Friedl
October 2020, Journal for immunotherapy of cancer,
Bettina Weigelin, and Marina Krause, and Peter Friedl
August 2012, European journal of immunology,
Bettina Weigelin, and Marina Krause, and Peter Friedl
June 2023, European journal of immunology,
Bettina Weigelin, and Marina Krause, and Peter Friedl
November 1998, Journal of immunology (Baltimore, Md. : 1950),
Bettina Weigelin, and Marina Krause, and Peter Friedl
September 2019, Cellular immunology,
Bettina Weigelin, and Marina Krause, and Peter Friedl
September 1984, The Journal of experimental medicine,
Bettina Weigelin, and Marina Krause, and Peter Friedl
March 2022, The Journal of experimental medicine,
Bettina Weigelin, and Marina Krause, and Peter Friedl
June 2006, Seminars in immunology,
Copied contents to your clipboard!